查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1917796

居家输液治疗市场－2026-2031年预测

Home Infusion Therapy Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计家庭输液治疗市场将从 2025 年的 294.5 亿美元成长到 2031 年的 424.5 亿美元，复合年增长率为 6.29%。

受医疗服务模式从医疗机构向患者家中转移这一根本性转变的推动，家庭输液治疗市场正经历显着且持续的成长。在这种模式下，包括抗生素、化疗药物、生物製药、疼痛管理疗法和营养支持在内的肠外给药，均在居住监督下于患者家中进行。患者偏好、临床疗效、监管支持和技术进步等因素的强强联合，推动了市场扩张，使家庭输液治疗成为以价值为导向的医疗保健策略的关键组成部分。

核心市场驱动因素与临床需求

推动居家医疗发展的关键因素在于其许多显着优势。研究一致表明，居家输液治疗的患者满意度高，临床疗效良好，通常与住院治疗的效果相当甚至更佳。从病人的观点来看，居家治疗提供了无与伦比的便利，既能维持日常生活规律并获得家人支持，又能减轻频繁就医带来的身心负担。这与患者日益增长的意愿相符，即在临床条件允许的情况下，选择在舒适且私密的家中接受治疗。

从临床角度来看，居家输液治疗是降低院内感染（HAI）风险的直接策略。透过缩短或淘汰住院时间，它可以减少患者接触医疗机构中常见的耐多药细菌和其他病原体的机会。这解决了急性照护中长期存在的挑战，并为医疗服务提供者和支付者提供了重要的动力，促使他们更加关注病人安全指标的改善。

人口和流行病学趋势进一步巩固了这一需求。需要长期或反覆静脉输液治疗的慢性疾病（例如自体免疫疾病和感染疾病）的日益普遍，造就了庞大的患者群体。同时，世界人口老化和行动不便疾病发生率的上升，使得患者前往诊所就诊的后勤挑战更加突出。居家输液治疗直接解决了这些就医障碍，确保了行动不便或受地理位置限制的患者能够持续获得治疗。

监管和技术驱动因素

支持性的法规结构和支付政策正在加速市场的正规化和扩张。主要市场近期对报销结构的修订扩大了福利范围，不仅涵盖输液药物，还包括相关的专业服务、护理以及居家安全用药所需的远端监测。这种经济上的核准对于扩大服务范围和鼓励医疗服务提供者参与至关重要。

技术创新正在提升居家输液的安全性、效率和覆盖范围。先进的互联便携式输液泵的研发，实现了精准给药，并可远端监测治疗依从性和输液泵功能。整合式数位化平台促进了药剂师、护理师、处方医生和患者之间的更紧密协作，简化了复杂的流程，并改善了整个医疗服务链中的沟通。

市场挑战与营运复杂性

儘管存在这些有利因素，但该市场仍面临巨大的营运障碍。家庭输液生态系统本身就十分复杂，需要多个相关人员之间的无缝协作，包括处方医生、专科药房、输液护理服务机构、支付方以及患者本身。资料系统脱节和沟通管道分散会导致治疗启动延迟、计费错误以及潜在的安全隐患。在非受控的医疗机构环境下，实施严格的病患教育和维持有效的临床监管仍然是至关重要的挑战，需要结构化的通讯协定和技术支援。

此外，谨慎筛选患者对于成功实施至关重要。并非所有患者或治疗方法必须包括临床病情稳定、居家环境安全，以及患者或看护者管理自身照护的能力。满足事先核准要求并向支付方证明成本效益，也是医疗服务提供者面临的持续挑战。

地理市场动态

北美是家庭输液服务领域最成熟、最先进的地区，预计将继续保持其市场主导地位。这一主导地位得益于有利的监管环境（积极扩大了报销范围）、慢性病高发、完善的专科药房服务体係以及技术的广泛应用。此外，众多拥有专门输液产品组合的成熟製药和医疗设备公司的存在，进一步巩固了该地区在推动创新和服务模式发展方面的核心地位。

竞争格局与策略展望

竞争格局由大型医疗保健公司、专业输液药局网路和医院附属医疗机构组成。主要参与者在临床专长、地域覆盖、支付方协议和技术整合方面展开竞争。策略重点领域包括开发综合疾病管理方案、投资于用于病患监测的预测分析以及建立策略联盟以创建能够管理病人历程的整合区域网络。

总之，家庭输液治疗市场正从小众替代方案转型为现代医疗保健服务的主流支柱。其成长主要得益于人口结构变化、促进诊疗点优化的经济奖励以及技术进步。对于业内专家而言，未来发展的关键在于规范护理通讯协定、推广可互通的医疗资讯科技解决方案以降低生态系统的复杂性，以及持续累积可靠的真实世界证据，以证明该模式在患者疗效、满意度和整体医疗成本方面的卓越价值。预计未来的发展将由不断拓展新的治疗领域以及与更广泛的居家照护计划进行更深入的整合所驱动。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 家庭输液治疗市场（依产品类型划分）

  • 介绍
  • 点滴帮浦
  • 点滴导管
  • 静脉输液装置
  • 其他的

6. 依给药途径分類的居家输液治疗市场

  • 介绍
  • 静脉注射
  • 皮下注射

7. 家庭输液治疗市场依应用领域划分

  • 介绍
  • 抗感染治疗
  • 肠外营养
  • 化疗
  • 疼痛管理药物
  • 水疗法
  • 其他的

8. 按地区分類的家庭输液治疗市场

  • 介绍
  • 北美洲
    • 依产品类型
    • 透过行政途径
    • 透过使用
    • 按国家/地区
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依产品类型
    • 透过行政途径
    • 透过使用
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 依产品类型
    • 透过行政途径
    • 透过使用
    • 按国家/地区
      • 德国
      • 法国
      • 英国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 依产品类型
    • 透过行政途径
    • 透过使用
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 以色列
      • 其他的
  • 亚太地区
    • 依产品类型
    • 透过行政途径
    • 透过使用
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 印尼
      • 泰国
      • 台湾
      • 其他的

第九章：竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • B. Braun SE
  • Baxter International Inc.
  • Becton Dickinson Company
  • Fresenius Kabi
  • ICU Medical Inc.
  • Terumo Corporation
  • Nipro Corporation
  • KORU Medical Systems
  • CODAN Companies
  • BPL Medical Technologies

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615770

Home Infusion Therapy Market, with a 6.29% CAGR, is projected to increase from USD 29.450 billion in 2025 to USD 42.455 billion in 2031.

The home infusion therapy market is experiencing significant and sustained growth, driven by a fundamental shift in care delivery from institutional settings to the patient's home. This model involves the administration of parenteral medications, including antibiotics, chemotherapy, biologics, pain management therapies, and nutritional support, within a patient's residence under clinical supervision. The market's expansion is propelled by a powerful convergence of patient preference, clinical efficacy, regulatory support, and technological advancement, positioning home infusion as a critical component of value-based healthcare strategies.

Core Market Drivers and Clinical Imperatives

A primary driver is the compelling array of benefits associated with home-based care. Studies consistently demonstrate high levels of patient satisfaction and positive clinical outcomes with home infusion, often comparable or superior to inpatient settings. From a patient perspective, it offers unparalleled convenience, preserving normalcy and family support while eliminating the logistical and emotional burdens of frequent hospital visits. This aligns with a clear and growing patient preference for receiving care in the comfort and privacy of their own homes whenever clinically appropriate.

Clinically, home infusion presents a direct strategy for mitigating the risk of Hospital-Acquired Infections (HAIs). By reducing or eliminating inpatient stays, it lowers patient exposure to multi-drug resistant organisms and other pathogens prevalent in healthcare facilities. This addresses a persistent challenge in acute care and is a significant motivator for providers and payers focused on improving patient safety metrics.

Demographic and epidemiological trends further solidify demand. The growing prevalence of chronic conditions requiring long-term or recurring intravenous treatment-such as certain cancers, autoimmune disorders, and infections-creates a substantial patient base. Concurrently, an aging global population and the rising incidence of mobility-impairing disorders make the logistical challenges of accessing clinic-based care more pronounced. Home infusion directly addresses these access barriers, ensuring continuity of therapy for patients with physical or geographic constraints.

Regulatory and Technological Enablers

Supportive regulatory frameworks and payment policies are accelerating market formalization and expansion. Recent updates to reimbursement structures in key markets have broadened coverage to include not only the infused drugs but also the associated professional services, nursing care, and remote monitoring required for safe home administration. This financial validation is crucial for scaling service offerings and incentivizing provider participation.

Technological innovation is enhancing the safety, efficiency, and reach of home infusion. The development of advanced, connected ambulatory infusion pumps allows for precise drug delivery and remote monitoring of therapy adherence and pump function. Integrated digital platforms facilitate better coordination among pharmacists, nurses, prescribers, and patients, streamlining the complex workflow and improving communication across the care continuum.

Market Challenges and Operational Complexities

Despite strong tailwinds, the market faces notable operational hurdles. The home infusion ecosystem is inherently complex, requiring seamless coordination among multiple stakeholders: prescribing physicians, specialty pharmacies, infusion nursing services, payers, and the patients themselves. Disconnected data systems and fragmented communication channels can lead to delays in therapy initiation, billing inaccuracies, and potential safety gaps. Ensuring rigorous patient education and maintaining robust clinical oversight outside a controlled facility environment remain paramount concerns that demand structured protocols and technological support.

Furthermore, successful implementation depends on careful patient selection. Not all patients or therapies are suitable for the home setting; criteria must include clinical stability, a safe home environment, and the patient's or caregiver's ability to manage certain aspects of care. Navigating prior authorization requirements and demonstrating cost-effectiveness to payers also present ongoing administrative challenges for providers.

Geographic Market Dynamics

North America is projected to maintain a dominant market share, serving as the most mature and advanced region for home infusion services. This leadership is underpinned by a favorable regulatory landscape that has proactively expanded reimbursement, a high prevalence of chronic diseases, a well-developed infrastructure of specialty pharmacy providers, and significant technological adoption. The presence of established pharmaceutical and medical device companies with dedicated infusion portfolios further reinforces the region's central role in driving innovation and service models.

Competitive Landscape and Strategic Outlook

The competitive environment includes a mix of large healthcare corporations, specialized infusion pharmacy networks, and hospital-affiliated providers. Key players compete on the basis of clinical expertise, geographic coverage, payer contracts, and technological integration. Strategic focus areas include the development of comprehensive disease management programs, investment in predictive analytics for patient monitoring, and the formation of strategic alliances to create integrated regional networks capable of managing the full patient journey.

In conclusion, the home infusion therapy market is transitioning from a niche alternative to a mainstream pillar of modern healthcare delivery. Its growth is structurally supported by demographic shifts, economic incentives favoring site-of-care optimization, and technological enablement. For industry experts, the critical path forward involves standardizing care protocols, advancing interoperable health IT solutions to reduce ecosystem complexity, and continuing to generate robust real-world evidence demonstrating the model's superior value in terms of patient outcomes, satisfaction, and total cost of care. The trajectory points toward continued expansion into new therapeutic areas and deeper integration with broader home-based care initiatives.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Home Infusion Therapy Market Segmentation

  • By Product Type
  • Infusion Pumps
  • Infusion Catheters
  • Intravenous IV Sets
  • Others
  • By Route of Administration
  • Intravenous
  • Subcutaneous
  • By Application
  • Anti-Infective Therapy
  • Parenteral Nutrition
  • Chemotherapy
  • Pain Management Drugs
  • Hydration Therapy
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HOME INFUSION THERAPY MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Infusion Pumps
  • 5.3. Infusion Catheters
  • 5.4. Intravenous IV Sets
  • 5.5. Others

6. HOME INFUSION THERAPY MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Intravenous
  • 6.3. Subcutaneous

7. HOME INFUSION THERAPY MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Anti-Infective Therapy
  • 7.3. Parenteral Nutrition
  • 7.4. Chemotherapy
  • 7.5. Pain Management Drugs
  • 7.6. Hydration Therapy
  • 7.7. Others

8. HOME INFUSION THERAPY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Route of Administration
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Route of Administration
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Route of Administration
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Israel
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Route of Administration
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. India
      • 8.6.4.3. Japan
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Taiwan
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. B. Braun SE
  • 10.2. Baxter International Inc.
  • 10.3. Becton Dickinson Company
  • 10.4. Fresenius Kabi
  • 10.5. ICU Medical Inc.
  • 10.6. Terumo Corporation
  • 10.7. Nipro Corporation
  • 10.8. KORU Medical Systems
  • 10.9. CODAN Companies
  • 10.10. BPL Medical Technologies

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations